Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Etilevodopa. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 6/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.64 |
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.64 |
| ▸ | RECQL | P46063 | 3/20 | 0.64 |
| ▸ | USP2 | O75604 | 2/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.64 |
| ▸ | HTR2A | P28223 | 2/20 | 0.64 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | LCK | P06239 | 2/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.64 |
| ▸ | EGFR | P00533 | 1/20 | 0.64 |
| ▸ | FYN | P06241 | 1/20 | 0.64 |
| ▸ | ALOX12 | P18054 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etilevodopa SCHEMBL1069939 | 1.00 | ALOX15 (0.64) | ALOX15KDM4EHIF1AHSD17B10SLC7A5 | |
| Etilevodopa SCHEMBL29634876 | 1.00 | ALOX15 (0.64) | ALOX15KDM4EHIF1AHSD17B10SLC7A5 | |
| Etilevodopa SCHEMBL7291700 | 0.98 | ALOX15 (0.62) | ALOX15KDM4EHIF1AHSD17B10SLC7A5 | |
| Etilevodopa SCHEMBL28278862 | 0.98 | ALOX15 (0.62) | ALOX15KDM4EHIF1AHSD17B10SLC7A5 | |
| Etilevodopa SCHEMBL7063390 | 0.98 | ALOX15 (0.62) | ALOX15KDM4EHIF1AHSD17B10SLC7A5 | |
| Etilevodopa SCHEMBL28209537 | 0.96 | ALOX15 (0.59) | ALOX15KDM4EHIF1AHSD17B10SLC7A5 | |
| Etilevodopa SCHEMBL28067523 | 0.94 | ALOX15 (0.57) | ALOX15KDM4EHIF1AHSD17B10SLC7A5 | |
| SCHEMBL6140024 | 0.88 | ALOX15 (0.60) | ALOX15KDM4EHIF1AHSD17B10SLC7A5 | |
| SCHEMBL15679070 | 0.88 | ALOX15 (0.60) | ALOX15KDM4EHIF1AHSD17B10SLC7A5 | |
| SCHEMBL11402716 | 0.87 | SLC7A5 (0.48) | ALOX15KDM4EHIF1AHSD17B10SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1326 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4292653-B1 | TARTARIC ACID SALTS OF [2-(3-FLUORO-5-METHANE-SULFONYLPHENOXY)ETHYL](PROPYL)AMINE | IRL 790 AB (SE) | 2026-03-18 | — | — | EP | claimed |
| US-12564596-B2 | Agents and methods for modulating pathogen activity | GRIFFITH UNIVERSITY (AU) | 2026-03-03 | — | — | US | claimed |
| EP-3768263-B1 | CONTINUOUS ADMINISTRATION OF PHARMACEUTICAL COMPOSITION FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | LOBSOR PHARMACEUTICALS AB (SE) | 2025-10-29 | — | — | EP | claimed |
| US-12251368-B2 | Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders | INTRANCE MEDICAL SYSTEMS INC. (US) | 2025-03-18 | — | — | US | claimed |
| US-20250057795-A1 | LIQUID COMPOSITIONS, EYE DROPS, AND METHODS FOR TREATMENT OF EYE DISEASES USING Levodopa FORMULATIONS | MARTENS JOHN A (US) | 2025-02-20 | — | — | US | claimed |
| US-20250041257-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING LEVODOPA, A DOPAMINE DECARBOXYLASE INHIBITOR AND A COMT INHIBITOR AND METHOD OF ADMINISTRATION THEREOF | INTRANCE MEDICAL SYSTEMS INC. | 2025-02-06 | — | — | US | claimed |
| US-12156858-B2 | Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof | INTRANCE MEDICAL SYSTEMS INC. (US) | 2024-12-03 | — | — | US | claimed |
| WO-2024218296-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | H. LUNDBECK A/S (DK) | 2024-10-24 | — | — | WO | claimed |
| EP-3870300-B1 | IMIDAZO[1,5-A]PYRAZINE COMPOUNDS AS PDE2 INHIBITORS | INTRA CELLULAR THERAPIES INC (US) | 2024-07-10 | — | — | EP | claimed |
| EP-4356907-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING LEVODOPA, A DOPAMINE DECARBOXYLASE INHIBITOR AND A COMTINHIBITOR AND METHOD OF ADMINISTRATION THEREOF | LobSor Pharmaceuticals Aktiebolag (SE) | 2024-04-24 | — | — | EP | claimed |
| US-20050203130-A1 | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists | PHARMANEUROBOOST N.V. (BE) | 2005-09-15 | — | — | US | claimed |
| US-20050203124-A1 | Compounds for the sustained reduction of body weight | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-15 | — | — | US | claimed |
| US-20050182090-A1 | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-18 | — | — | US | claimed |
| WO-2005070427-A1 | COMPOUNDS FOR THE SUSTAINED REDUCTION OF BODY WEIGHT | NEUROSEARCH A/S (DK) | 2005-08-04 | — | — | WO | claimed |
| WO-2005053796-A1 | USE OF D4 AND 5-HT2A ANTAGONISTS, INVERSE AGONISTS OR PARTIAL AGONISTS | B & B BEHEER NV (BE) | 2005-06-16 | — | — | WO | claimed |
| EP-1541197-A1 | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists | B&B Beheer NV (BE) | 2005-06-15 | — | — | EP | claimed |
| EP-1507518-A1 | COMBINATION IMMEDIATE RELEASE CONTROLLED RELEASE LEVODOPA/CARBIDOPA DOSAGE FORMS | Impax Laboratories, Inc. (US) | 2005-02-23 | — | — | EP | claimed |
| US-20040166159-A1 | Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa | IMPAX LABORATORIES, INC. | 2004-08-26 | — | — | US | claimed |
| WO-2003101432-A1 | COMBINATION IMMEDIATE RELEASE CONTROLLED RELEASE LEVODOPA/CARBIDOPA DOSAGE FORMS | IMPAX LABORATORIES, INC. (US) | 2003-12-11 | — | — | WO | claimed |
| US-20030228360-A1 | Combination immediate release controlled release levodopa/carbidopa dosage forms | IMPAX LABORATORIES, INC. | 2003-12-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12564596-B2 | Agents and methods for modulating pathogen activity | C3AR1, HTR3A, CHRM3 | DRD3 128/4885ALOX15 3036/4885KDM4E 3481/4885 |
| US-20050203124-A1 | Compounds for the sustained reduction of body weight | SLC6A2, SLC6A3, SLC6A4 | DRD3 202/4885ALOX15 2157/4885KDM4E 1716/4885 |
| US-12251368-B2 | Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders | COMT, DBH, DDC | DRD3 301/4885ALOX15 1004/4885KDM4E 3114/4885 |
| US-12156858-B2 | Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof | COMT, DDT, DDC | DRD3 74/4885ALOX15 1508/4885KDM4E 2546/4885 |
| US-20050182090-A1 | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist | SLC6A2, SLC6A3, SLC18A2 | DRD3 49/4885ALOX15 2151/4885KDM4E 3295/4885 |
| US-20250057795-A1 | LIQUID COMPOSITIONS, EYE DROPS, AND METHODS FOR TREATMENT OF EYE DISEASES USING Levodopa FORMULATIONS | LOX, LOXL1, PDE6C | DRD3 426/4885ALOX15 69/4885KDM4E 1805/4885 |
| US-20050203130-A1 | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists | HTR2A, HTR4, HTR5A | DRD3 32/4885ALOX15 1074/4885KDM4E 1845/4885 |
| US-20250041257-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING LEVODOPA, A DOPAMINE DECARBOXYLASE INHIBITOR AND A COMT INHIBITOR AND METHOD OF ADMINISTRATION THEREOF | COMT, DDT, DDC | DRD3 52/4885ALOX15 1795/4885KDM4E 2245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.